Publicité LinkedIn techbio : comment Owkin et Insilico Medicine génèrent de la demande

Find out how Owkin helps you explore one patient across multiple data points. Benefit from six advanced modalities, including spatial and single-cell, and access richly characterised clinical datasets. Find the right fit faster and get to better insights for your research. Access unique multimodal data across 11 oncology indications Learn more

Explore newly released multimodal oncology data, from spatial to single-cell. Book a meeting to stay ahead of your research. Don’t miss out on the best multimodal patient data for your research Learn more

Find out how Owkin gives you early access to new multimodal datasets across 11 indications. Discover deeper insights sooner and start exploring data that moves your research forward. Be first to access newly available multimodal oncology data Learn more

Find out how Owkin helps you access deeply characterised oncology datasets aligned to your clinical questions. Unlock better insights today to completely support your research needs. Discover multimodal data built for your research question Learn more

Explore deep multimodal patient data in NSCLC and beyond, from spatial to single-cell. Book a meeting to stay ahead of your research. Don’t miss out on the best multimodal patient data for your research Learn more

Discovering and developing new drugs takes years, costs billions, and fails often. 🌟Did you know the journey from identifying a target to a development candidate takes 2.5-4 years? We are rewriting the rules of #drugdiscovery with Pharma.ai, a proprietary platform that harnesses the full power of #GenerativeAI across #biology, #chemistry, and clinical development. Built on Amazon Web Services (AWS) secure…

Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size. Test the MMAI Gym Today! Learn more

⚡ 10x Smaller, 10x Faster: New SOTA Benchmarks for Pharma #LLMs Most LLMs fail and continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training. Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a #drugdiscovery powerhouse. Despite its small footprint, it is…

Most frontier models continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training. Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or…

🚀 O3DC is live today We are excited to share the launch of the Open Drug Discovery & Development Consortium (#O3DC). Our first shared resource is now public: a living Benchmark Index that already includes 115 open benchmarks across 10 categories and 15 consortia & initiatives, and is being updated and populated every day. What you’ll find: ✅ What each benchmark actually measures ✅ Who maintains it ✅ Live GitHub…